Bronchopulmonary Dysplasia (BPD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Bronchopulmonary Dysplasia (BPD) Emerging Therapy and TPP Insights

Thelansis’s “Bronchopulmonary Dysplasia (BPD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Bronchopulmonary Dysplasia (BPD) Overview

Bronchopulmonary dysplasia (BPD) is the most prevalent chronic respiratory morbidity of prematurity, predominantly afflicting extremely low birth weight (ELBW) infants born prior to 28 weeks of gestation. In the modern post-surfactant era, the pathogenesis of “new BPD” is fundamentally characterized by a critical arrest of both alveolarization and pulmonary microvascular development—resulting in fewer, larger, and highly simplified alveoli—driven by the synergistic, iatrogenic insults of mechanical ventilation (volutrauma and barotrauma) and oxygen toxicity acting upon a profoundly immature and highly inflammatory respiratory system. Clinically defined by a sustained requirement for supplemental oxygen or positive pressure respiratory support at 36 weeks post-menstrual age, the disease initiates a catastrophic cascade that heavily predisposes surviving infants to lifelong sequelae, most notably severe pulmonary hypertension, reactive airway disease, and significant neurodevelopmental impairment. Because definitive pharmacological cures remain elusive, the modern therapeutic paradigm relies heavily on aggressive prevention and lung-protective strategies. The standard of care strictly prioritizes the avoidance of invasive intubation by leveraging early non-invasive continuous positive airway pressure (CPAP), synergistically combined with targeted exogenous surfactant replacement, caffeine citrate therapy, optimized nutritional fortifiers, and the highly judicious administration of postnatal systemic or inhaled corticosteroids to mitigate rampant inflammation and facilitate successful weaning from respiratory support.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Bronchopulmonary Dysplasia (BPD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026